Sign In
Buy NMRA
$1.61
+0.0100 (+0.625%)
At Close: Aug 05, 2026
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $7.57 Consensus Target Price from Analysts
02:46am, Wednesday, 26'th Nov 2025
Shares of Neumora Therapeutics, Inc. (NASDAQ: NMRA - Get Free Report) have been assigned a consensus recommendation of "Hold" from the ten ratings firms that are covering the stock, Marketbeat Ratings
Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
07:00am, Thursday, 06'th Nov 2025
Announced class-leading data from diet-induced obesity (DIO) mouse model with NMRA-215, a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor, and expect to initiate Phase 1 study
Neumora Therapeutics to Participate in Upcoming Conferences in November
07:00am, Monday, 03'rd Nov 2025
WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that
Neumora Therapeutics, Inc. (NASDAQ:NMRA ) Discusses NMRA-215 Preclinical Results and Portfolio Updates, Including Obesity and Alzheimer's Disease Programs October 27, 2025 8:00 AM EDT Company Particip
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898
07:00am, Monday, 27'th Oct 2025
NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora's M4 franchise; both programs have potential best-in-class pharmacology
Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model
06:30am, Monday, 27'th Oct 2025
NMRA-215 demonstrated class-leading weight loss of up to 19% as a monotherapy with semaglutide-like induction NMRA-215 demonstrated best-in-class weight loss of up to 26% in combination with semaglu
Neumora Therapeutics to Host Virtual R&D Day on October 27
07:00am, Wednesday, 01'st Oct 2025
WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that
Neumora Therapeutics to Participate in Upcoming Conferences in September
07:00am, Tuesday, 02'nd Sep 2025
WATERTOWN, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs tha
Neumora Therapeutics, Inc. (NMRA) Q2 2025 Earnings Call Transcript
02:41am, Thursday, 07'th Aug 2025
Neumora Therapeutics, Inc. (NASDAQ:NMRA ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Daljit Singh Aurora - Corporate Participant Chief Operationg & Development off
Neumora (NMRA) Q2 Loss Improves 10%
07:46pm, Wednesday, 06'th Aug 2025
Neumora Therapeutics (NMRA -4.22%), a clinical-stage neuroscience company developing targeted therapies for brain diseases, released its second quarter 2025 results on August 6, 2025. The most signifi
Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
04:05pm, Wednesday, 06'th Aug 2025
Initiated Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study with M4 positive allosteric modulator (PAM) NMRA-861, with data expected in the first quarter of 2026 Announces prioriti
Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
07:00am, Wednesday, 23'rd Jul 2025
WATERTOWN, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861
07:00am, Wednesday, 09'th Jul 2025
NMRA-861 has potential best-in-class pharmacology, which may enable a more favorable therapeutic profile No convulsions observed in pre-clinical studies conducted in multiple species, including rabbit
Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law Firm
09:40pm, Tuesday, 27'th May 2025
NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Neumora Therapeutics, Inc. (NASDAQ: NMRA) brea
Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law Firm
03:50pm, Wednesday, 14'th May 2025
NEW YORK , May 14, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Neumora Therapeutics, Inc. (NASDAQ: NMRA) breac
